Seabra-Gomes_Cardiology_book_temp 02/02/2010 15:30 Page 52
Cardiogenic Shock
15. Kushner FG, Hand M, Smith SC, et al., 2009 Focused 28. IABP-SHOCK II trial. Available at: clinicaltrials.gov/ct2/ cardiogenic shock after primary angioplasty, Int J Cardiol,
updates: ACC/AHA Guidelines for the management of show/NCT00491036, accessed 26 November 2009). 2008;128:214–17.
patients with ST-elevation myocardial infarction and 29. Hochman JS, Cardiogenic shock complicating acute 41. Thiele H, Smalling RW, Schuler GC, Percutaneous left
ACC/AHA/SCAI Guidelines on percutaneous coronary myocardial infarction: expanding the paradigm, Circulation, ventricular assist devices in acute myocardial infarction
intervention, J Am Coll Cardiol, 2009;54: in press. 2003;107:2998–3002. complicated by cardiogenic shock, Eur Heart J, 2007;28:
16. Jeger RV, Harkness SM, Ramanathan K, et al., SHOCK 30. Cotter G, Kaluski E, Milo O, et al., LINCS: L-NAME (a NO 2057–63.
investigators. Emergency revascularization in patients synthase inhibitor) in the treatment of refractory 42. Burkhoff D, Cohen H, Brunckhorst C, et al., A randomized
with cardiogenic shock on admission: a report from the cardiogenic shock. A prospective randomized study, multicenter clinical study to evaluate the safety and
SHOCK trial and registry, Eur Heart J, 2006;27:664–70. Eur Heart J, 2003;24:1287–95. efficacy of the TandemHeart percutaneous ventricular
17. Fincke R, Hochman JS, Lowe AM, et al., Cardiac power is 31. Dzavík V, Cotter G, Reynolds HR, et al., SHOCK-2 assist device versus conventional therapy with intraaortic
the strongest hemodynamic correlate of mortality in investigators. Effect of nitric oxide synthase inhibition on balloon pumping for treatment of cardiogenic shock, Am
cardiogenic shock: a report from the SHOCK trial registry, haemodynamics and outcome of patients with persistent Heart J, 2006;152:469 e1–e8.
J Am Coll Cardiol, 2004;44:340–48. cardiogenic shock complicating acute myocardial 43. Thiele H, Sick P, Boudriot E, et al., Randomized
18. Cohen MG, Kelly RV, Kong DF, et al., Pulmonary artery infarction: a phase II dose-ranging study, Eur Heart J, comparison of intra-aortic balloon support with a
catheterization in acute coronary syndromes: insights 2007;28:1109–16. percutaneous left ventricular assist device in patients
from the GUSTO IIb and GUSTO III trials, Am J Med, 32. The TRIUMPH Investigators, Alexander JH, Reynolds HR, with revascularized acute myocardial infarction
2005;118:482–8. Stebbins AL, et al., Effect of tilarginine acetate in patients complicated by cardiogenic shock, Eur Heart J,
19. Kohsaka S, Menon V, Lowe AM, et al., Systemic with acute myocardial infarction and cardiogenic shock. 2005;26:1276–83.
inflammatory response syndrome after acute myocardial The TRIUMPH randomized controlled trial, JAMA, 44. Seyfarth M, Sibbing D, Bauer I, et al., A randomized
infarction complicated by cardiogenic shock, Arch Intern 2007;297:1657–66. clinical trial to evaluate the safety and efficacy of a
Med, 2005;165:1643–50. 33. Ndrepepa G, Schömig A, Kastrati A, Lack of benefit from percutaneous left ventricular assist device versus intra-
20. Dickstein K, Cohen-Solal A, Filippatos G, et al., ESC nitric oxide synthase inhibition in patients with aortic balloon pumping for treatment of cardiogenic
Guidelines for the diagnosis and treatment of acute and cardiogenic shock. Looking for reasons, JAMA, shock caused by myocardial infarction, J Am Coll Cardiol,
chronic heart failure 2008: the Task Force for the 2007;297:1711–13. 2008;52:1584–8.
Diagnosis and Treatment of Acute and Chronic Heart 34. Roe MT, Ohman EM, Maas AC, et al., Shifting the open- 45. Cheng JM, den Uil CA, Hoeks SE, et al., Percutaneous left
Failure 2008 of the European Society of Cardiology, artery hypothesis downstream: the quest for optimal ventricular assist devices vs. intra-aortic balloon pump
Eur Heart J, 2008;29:2388–2442. reperfusion, J Am Coll Cardiol, 2001;37:9–18. counterpulsation for treatment of cardiogenic shock: a
21. Katz JN, Stebbins AL, Alexander JH, et al., Predictors of 35. Mehta SR, Yusuf S, Díaz R, et al., Effect of glucose-insulin- meta-analysis of controlled trials, Eur Heart J,
30-day mortality in patients with refractory cardiogenic potassium infusion on mortality in patients with acute ST- 2009;30:2102–8.
shock following acute myocardial infarction despite a segment elevation myocardial infarction: the CREATE- 46. ISAR-SHOCK, Efficacy study of LV assist device to treat
patent infarct artery, Am Heart J, 2009;158:680–87. ECLA randomized controlled trial, JAMA, 2005;293:437–46. patients with cardiogenic shock. Available at:
22. Graziani G, Bordone G, Bellato V, et al., Role of the kidney 36. APEX AMI Investigators, Armstrong PW, Granger CB, clinicaltrials.gov/ct2/show/NCT00417378 (accessed 26
in plasma cytokine removal in sepsis syndrome: a pilot Adams PX, et al., Pexelizumab for acute ST-elevation November 2009.)
study, J Nephrol, 2006;19:176–82. myocardial infarction in patients undergoing primary 47. Comparison of standard treatment versus standard
23. Klein LW, Shaw RE, Krone RJ, et al., Mortality after percutaneous coronary intervention: a randomized treatment plus extracorporeal life support (ECLS) in
emergent percutaneous coronary intervention in controlled trial, JAMA, 2007;297:43–51. myocardial infarction complicated with cardiogenic
cardiogenic shock secondary to acute myocardial 37. DELTA MI Investigators, Bates E, Bode C, Costa M, et al., shock. Available at: clinicaltrials.gov/ct2/show/
infarction and usefulness of a mortality prediction model, Intracoronary KAI-9803 as an adjunct to primary NCT00314847, accessed 26 November 2009.)
Am J Cardiol, 2005;96:35–41. percutaneous coronary intervention for acute ST- 48. Mertens P, Maes A, Nuyts J, et al., Recombinant P-selectin
24. Montalescot G, Antoniucci D, Kastrati A, et al., Abciximab segment elevation myocardial infarction, Circulation, glycoprotein ligand-immunoglobulin, a P-selectin
in primary coronary stenting of ST-elevation myocardial 2008;117:886–96. antagonist, as an adjunct to thrombolysis in acute
infarction: a European meta-analysis on individual 38. Meyer K, Schipke JD, Klocke RC, et al., Inotropic, myocardial infarction. The P-Selectin Antagonist Limiting
patients’ data with long-term follow-up, Eur Heart J, vasodilating and preconditioning actions of levosimendan Myonecrosis (PSALM) trial, Am Heart J, 2006;152:125.e1–8.
2007;28:443–9. in the heart, Thorac Cardiovasc Surg, 2008;56:379–85. 49. Baran KW, Nguyen M, McKendall GR, et al., Double-blind,
25. Kantrowitz A, Tjonneland S, Freed PS, et al., Initial clinical 39. Moiseyev VS, Põder P, Andrejevs N, et al., Safety and randomized trial of an anti-CD18 antibody in conjunction
experience with intraaortic balloon pumping in efficacy of a novel calcium sensitizer, levosimendan, in with recombinant tissue plasminogen activator for acute
cardiogenic shock, JAMA, 1968;203:113–18. patients with left ventricular failure due to an acute myocardial infarction: limitation of myocardial infarction
26. Thiele H, Schuler G, Cardiogenic shock: to pump or not to myocardial infarction. A randomized, placebo-controlled, following thrombolysis in acute myocardial infarction
pump?, Eur Heart J, 2009;30:389–90. double-blind study (RUSSLAN), Eur Heart J, (LIMIT AMI) study, Circulation, 2001;104:2778–83.
27. Sjauw KD, Engström AE, Vis MM, et al., A systematic 2002;23:1422–32. 50. Hoshida S, Yamashita N, Otsu K , et al., FR167653, a
review and meta-analysis of intra-aortic balloon pump 40. Dominguez-Rodriguez A, Samimi-Fard S, Garcia-Gonzalez cytokine-suppressive agent, reduces myocardial
therapy in ST-elevation myocardial infarction: should we MJ, et al., Effects of levosimendan versus dobutamine on ischemia-reperfusion injury in rats, Cytokines Cell Mol Ther,
change the guidelines?, Eur Heart J, 2009;30:459–68. left ventricular diastolic function in patients with 2000;6:165–70.
52 EUROPEAN CARDIOLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92